The 5 -reductase inhibitors can be helpful for patients with prostate volume >40 mL [6]. The muscarinic receptor antagonists and phosphodiesterase type 5 inhibitors can be used for storage symptoms [6]. Transurethral resection of the prostate is the standard surgical treatment for prostate volume 30 to 80 mL, with surgery or transurethral holmium laser enucleation for prostate volume >80 mL [6]. Other interventional options include laser ablation, transurethral needle or microwave ablation, transurethral resection, and prostate artery embolization. Treatment decisions vary by prostate volume and patient comorbidities [6,7]. aMayo Clinic, Jacksonville, Florida. bPanel Chair, University of Chicago, Chicago, Illinois. cPanel Vice-Chair, Duke University Medical Center, Durham, North Carolina. dMemorial Sloan Kettering Cancer Center, New York, New York. eMcGill University, Montreal, Quebec, Canada. fMayo Clinic, Rochester, Minnesota. gUrology Clinics of North Texas, Dallas, Texas; American Urological Association. hUniversity of Pennsylvania School of Medicine, Philadelphia, Pennsylvania; American Society of Nephrology. iUPMC, Pittsburgh, Pennsylvania; American Urological Association. jCleveland Clinic, Cleveland, Ohio. kStanford University Medical Center, Stanford, California. lOttawa Hospital Research Institute and the Department of Radiology, The University of Ottawa, Ottawa, Ontario, Canada. mEmory University Hospital, Atlanta, Georgia. nNational Institutes of Health, Bethesda, Maryland. oThe University of Texas MD Anderson Cancer Center, Houston, Texas. pUniversity of Washington, Seattle Cancer Care Alliance, Seattle, Washington. qSpecialty Chair, University of Alabama at Birmingham, Birmingham, Alabama. The American College of Radiology seeks and encourages collaboration with other organizations on the development of the ACR Appropriateness Criteria through society representation on expert panels.
Lower Urinary Tract Symptoms Suspicion of Benign Prostatic Hyperplasia. The 5 -reductase inhibitors can be helpful for patients with prostate volume >40 mL [6]. The muscarinic receptor antagonists and phosphodiesterase type 5 inhibitors can be used for storage symptoms [6]. Transurethral resection of the prostate is the standard surgical treatment for prostate volume 30 to 80 mL, with surgery or transurethral holmium laser enucleation for prostate volume >80 mL [6]. Other interventional options include laser ablation, transurethral needle or microwave ablation, transurethral resection, and prostate artery embolization. Treatment decisions vary by prostate volume and patient comorbidities [6,7]. aMayo Clinic, Jacksonville, Florida. bPanel Chair, University of Chicago, Chicago, Illinois. cPanel Vice-Chair, Duke University Medical Center, Durham, North Carolina. dMemorial Sloan Kettering Cancer Center, New York, New York. eMcGill University, Montreal, Quebec, Canada. fMayo Clinic, Rochester, Minnesota. gUrology Clinics of North Texas, Dallas, Texas; American Urological Association. hUniversity of Pennsylvania School of Medicine, Philadelphia, Pennsylvania; American Society of Nephrology. iUPMC, Pittsburgh, Pennsylvania; American Urological Association. jCleveland Clinic, Cleveland, Ohio. kStanford University Medical Center, Stanford, California. lOttawa Hospital Research Institute and the Department of Radiology, The University of Ottawa, Ottawa, Ontario, Canada. mEmory University Hospital, Atlanta, Georgia. nNational Institutes of Health, Bethesda, Maryland. oThe University of Texas MD Anderson Cancer Center, Houston, Texas. pUniversity of Washington, Seattle Cancer Care Alliance, Seattle, Washington. qSpecialty Chair, University of Alabama at Birmingham, Birmingham, Alabama. The American College of Radiology seeks and encourages collaboration with other organizations on the development of the ACR Appropriateness Criteria through society representation on expert panels.